Clinical Trials Directory

Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • procedure : Grafting of Autologous Cultured Revertant Keratinocytes

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Clinical diagnosis of EB (simplex, junctional or dystrophic) - Areas of revertant skin that has been confirmed by biopsy - 18 years or older subject willing and able to give consent - Confirmation of EB diagnosis by immunofluorescence (IF), electron microscopy (EM), and genetic testing confirming mutation - At least 100 to 200 cm2 of open erosions on the trunk and/or extremities suitable for skin grafting - Able to undergo adequate anesthesia to allow grafting procedures to take place

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Emily S Gorell, MS
Not Recruiting

Footer Links: